CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 ...

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema ... but frequently do not eliminate all, angioedema attacks and require lifelong administration.

ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients ... in the management of hereditary angioedema, offering people living with this ...

Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

(berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Limitations of use ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...